Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.
2012
DOI: 10.1038/jid.2012.146
|View full text |Cite
|
Sign up to set email alerts
|

Mutations in the Prostaglandin Transporter SLCO2A1 Cause Primary Hypertrophic Osteoarthropathy with Digital Clubbing

Abstract: Abbreviations: HPGD, 15-hydroxyprostaglandin dehydrogenase; NMD, nonsense-mediated decay; PG, prostaglandin; PHO, hypertrophic osteoarthropathy www.jidonline.org 2473 J Busch et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
20
0
2

Year Published

2012
2012
2024
2024

Publication Types

Select...
6
3
1

Relationship

1
9

Authors

Journals

citations
Cited by 42 publications
(25 citation statements)
references
References 12 publications
0
20
0
2
Order By: Relevance
“…Homozygous mutations in the 15-hydroxyprostaglandin dehydrogenase (HPGD) gene, encoding the major enzyme responsible for prostaglandin degradation, or the solute carrier organic anion transporter family member 2A1 (SLCO2A1) gene, which encodes a prostaglandin transporter protein (PGT) responsible for intracellular prostaglandin up-take, have been identified as underlying cause [88][89][90][91][92][93][94][95]. Increased levels of circulating PGE 2 in PHO patients together with the observation, that infused PGE 2 (for therapeutic reasons in treating newborns with duct-dependent congenital heart disease) can induce skeletal changes similar to PHO, suggest that increased availability of systemic PGE 2 is responsible for the symptoms observed in PHO patients [88,91,96].…”
Section: Primary Hypertrophic Osteoarthropathy (Pho)mentioning
confidence: 99%
“…Homozygous mutations in the 15-hydroxyprostaglandin dehydrogenase (HPGD) gene, encoding the major enzyme responsible for prostaglandin degradation, or the solute carrier organic anion transporter family member 2A1 (SLCO2A1) gene, which encodes a prostaglandin transporter protein (PGT) responsible for intracellular prostaglandin up-take, have been identified as underlying cause [88][89][90][91][92][93][94][95]. Increased levels of circulating PGE 2 in PHO patients together with the observation, that infused PGE 2 (for therapeutic reasons in treating newborns with duct-dependent congenital heart disease) can induce skeletal changes similar to PHO, suggest that increased availability of systemic PGE 2 is responsible for the symptoms observed in PHO patients [88,91,96].…”
Section: Primary Hypertrophic Osteoarthropathy (Pho)mentioning
confidence: 99%
“…Additional manuscript for isolation of SLCO2A1 mutation in PDP patients were published [24] in revision. Fig.…”
Section: Note Added In Proofmentioning
confidence: 99%
“…Loss‐of‐function (LOF) mutations in the SLCO2A1 gene, encoding a prostaglandin transporter have been described to cause pediatric‐onset chronic nonspecific multiple ulcers of the small intestine, accompanied with persistent blood and protein‐losing enteropathy in the Japanese population. Mutations in SLCO2A1 have been previously reported as the cause of primary hypertrophic osteoarthropathy (PHO) . Three out of five male patients with chronic enteropathy associated with SLCO2A1 had all of the major clinical features of PHO as well, such as digital clubbing, periostosis, and pachydermia.…”
Section: Monogenic Forms Of Inflammatory Bowel Diseasementioning
confidence: 99%